Measures are imminent when the MFDS begins testing by collecting finished products of Metformin, which are used as diabetes treatments.

In last December, an excess of NDMA (N-nitrosodimethylamine), a carcinogen, was detected in Metformin preparations in Singapore. Since then, the MFDS has been conducting extensive investigations. After collecting and inspecting about 900 raw materials, it is believed that the investigation process is being expanded to the finished product and the process of selecting products with excess impurities is in progress.

Although the results of the investigation are still unknown, some people have analyzed that NDMA was detected in the raw material and then expa